Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history who has had a diagnosis of psoriasis for at least 12 months and stable moderate to severe chronic plaque psoriasis~* Subject is a candidate for systemic therapy or phototherapy and has active psoriasis despite treatment with topical agents.~* Subject was able and willing to self-administer sc injections or had available qualified person(s) to administer sc injections.~* Male subjects must hve been vasectomized or practicing birth control.~Exclusion Criteria:~* Previous systemic anti-TNF therapy.~* Prior use of MTX.~* Known hypersensitivity to the constituents of adalimumab.~* Systemic therapy for psoriasis for at least 4 weeks prior to Baseline; except for biologic therapies, which must be discontinued at least 12 weeks prior to enrollment.~* Topical psoriasis therapy for at least 2 weeks prior to Baseline, except for non-corticosteroid shampoos, bland (no alpha or beta hydroxy) emollients and low potency topical corticosteroids on the palms, soles, face, inframammary area, and groin only.~* Use of tanning beds, excessive sun exposure, or phototherapy (UVB, UVA), for at least 2 weeks prior to Baseline.~* Use of PUVA for at least 4 weeks prior to Baseline.~* Use of oral or injectable corticosteroids during the study.~* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study.~* Female subject who is pregnant or breast feeding or considering becoming pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None
- B (Type: ACTIVE_COMPARATOR): None
- C (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).